RGDXQ (Response Genetics) Dividend Payout Ratio: 0.00 (As of Dec. 2015)


What is Response Genetics Dividend Payout Ratio?

Response Genetics RGDXQ -98.00% Dividend Payout Ratio is 0.00 as of Dec. 2015.

The Dividend Payout Ratio is the measure of dividends paid out to shareholders relative to the company's net income. It is calculated as the Dividends per Share divided by the Earnings per Share (Diluted) during the same time period. Response Genetics's Dividend Payout Ratio for the months ended in Dec. 2015 was 0.00.

The historical rank and industry rank for Response Genetics's Dividend Payout Ratio or its related term are showing as below:


RGDXQ's Dividend Payout Ratio is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 0.49
* Ranked among companies with meaningful Dividend Payout Ratio only.

As of today (2026-07-03), the Dividend Yield % of Response Genetics is 0.00%.

Response Genetics's Dividends per Share for the months ended in Dec. 2015 was $0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

* Please note that "special dividend" is not included in the calculation of dividend per share and related fields.


Response Genetics (OTCPK:RGDXQ) Dividend Payout Ratio Explanation

In dividends investing, Dividend Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.


Response Genetics Dividend Payout Ratio Related Terms


Response Genetics Dividend Payout Ratio Historical Data

* Premium members only.

The historical data trend for Response Genetics's Dividend Payout Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Response Genetics Dividend Payout Ratio Chart

Response Genetics Annual Data
Trend Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15
Dividend Payout Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Response Genetics Quarterly Data
Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Dec15
Dividend Payout Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

RGDXQ vs PSID, GBSN, ETAH: Dividend Payout Ratio Comparison

For the Diagnostics & Research subindustry, Response Genetics's Dividend Payout Ratio, along with its competitors' market caps and Dividend Payout Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Response Genetics Dividend Payout Ratio vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Response Genetics's Dividend Payout Ratio distribution charts can be found below:

* The bar in red indicates where Response Genetics's Dividend Payout Ratio falls into.



Response Genetics Dividend Payout Ratio Calculation

The Dividend Payout Ratio is the measure of dividends paid out to shareholders relative to the company's net income. It is calculated as the Dividends per Share divided by the Earnings per Share (Diluted) during the same time period.

Response Genetics's Dividend Payout Ratio for the fiscal year that ended in Dec. 2015 is calculated as

Dividend Payout Ratio=Dividends per Share (A: Dec. 2015 )/ EPS without NRI (A: Dec. 2015 )
=0/ -1.988
=N/A

Response Genetics's Dividend Payout Ratio for the quarter that ended in Dec. 2015 is calculated as

Dividend Payout Ratio=Dividends per Share (Q: Dec. 2015 )/ EPS without NRI (Q: Dec. 2015 )
=0/ 0
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Dividend Payout Ratio →
What does a Dividend Payout Ratio of 0.00 mean?
Response Genetics (RGDXQ) has a Dividend Payout Ratio of 0.00 as of Dec. 2015. Dividend payout ratio is the percent of company earnings paid out as dividends. View historical data on Response Genetics and its competitors.
Is Response Genetics' Dividend Payout Ratio too high?
Response Genetics' current Dividend Payout Ratio is 0.00.
How does Response Genetics' Dividend Payout Ratio compare to PSID and GBSN?
Response Genetics' Dividend Payout Ratio of 0.00 can be compared against companies in the Medical Diagnostics & Research industry. The industry median Dividend Payout Ratio is 0.49. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Dividend Payout Ratio for a Medical Diagnostics & Research company?
The median Dividend Payout Ratio among Medical Diagnostics & Research companies is 0.49, based on 55 companies in the industry. Companies in the top quartile (top 25%) have a Dividend Payout Ratio significantly above this median, while those in the bottom quartile fall well below. However, Dividend Payout Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Dividend Payout Ratio mean?
A high Dividend Payout Ratio can signal that a stock is expensive relative to its fundamentals. Dividend payout ratio is the percent of company earnings paid out as dividends. View historical data on Response Genetics and its competitors. For the Medical Diagnostics & Research industry, the median Dividend Payout Ratio is 0.49 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Response Genetics's current Dividend Payout Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Response Genetics stock overvalued right now?
Response Genetics (RGDXQ) has a current Dividend Payout Ratio of 0.00. The current Dividend Payout Ratio is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Dividend Payout Ratio calculated?
Dividend Payout Ratio is calculated from a company's financial statements. For Response Genetics (RGDXQ), the current Dividend Payout Ratio is 0.00 as of Dec. 2015. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Response Genetics Business Description

Address 201 Route 17 North, 2nd Floor, Rutherford, NJ, USA, 07070
Response Genetics Inc develops and sells diagnostic tests. It provides molecular- and biomarker-based tests and services which enables physicians to personalize the clinical management of each individual patient by providing genomic information to diagnose, monitor and inform cancer treatment. The group generates revenue from providing Biopharma Services, Clinical Services, and Discovery Services, of which majority of the revenue is derived from providing Biopharma Services. Biopharma services provide companies with customized solutions for patient stratification and treatment selection through molecular- and biomarker-based testing services, customized assay development and trial design consultation. The firm operates in the US and internationally and generates prime revenue from the US.